Articles from Genmab A/S and AbbVie
Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) clarified primary endpoints from their Phase 3 EPCORE DLBCL-1 trial of epcoritamab (DuoBody-CD3xCD20) in relapsed or refractory DLBCL. The study compares subcutaneous epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy (R-GemOx or BR) in adults ineligible for autologous stem cell transplant. Topline results were announced Jan 16, 2026.
How this was made
The 30-second read
Why it matters
This update focuses on clarifying the primary endpoints for epcoritamab versus investigator’s choice chemoimmunotherapy in adults with relapsed/refractory DLBCL ineligible for autologous stem cell transplantation.
Market read
Endpoint clarification can influence how investors model trial success, but the article provides no new efficacy or safety figures.
What to watch
Traders may be waiting for the next concrete catalyst, such as full results, regulatory filing timelines, or updated statistical analysis plan details.
Background
Genmab and AbbVie previously announced topline results for the Phase 3 EPCORE DLBCL-1 study and later presented additional results at EHA 2026.
Ticker impact
Genmab and AbbVie clarify primary endpoints for the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in R/R DLBCL.
Likely modest, sentiment-neutral to slightly positive, unless the clarification changes the statistical interpretation versus prior topline.
The article does not provide new efficacy/safety numbers, but it does update how the primary endpoints are framed after prior topline and EHA presentation.
AbbVie is named alongside Genmab in clarifying primary endpoints for the Phase 3 EPCORE DLBCL-1 epcoritamab study.
Limited near-term impact; could support incremental optimism if investors were uncertain about endpoint definitions.
No new trial results are disclosed here, only clarification of primary endpoints after earlier topline and conference materials.
Market effects
Adds incremental detail to the competitive landscape for bispecific antibodies in DLBCL, but without new performance data.
No clear regional read-through beyond US-listed biotech sentiment.
Limited global impact; primarily affects investor interpretation of a specific Phase 3 program.
Counterpoint
Endpoint clarification may not change the underlying likelihood of success, so the market may discount it quickly.
Key entities
- clinical_trialEPCORE DLBCL-1
Phase 3 study evaluating monotherapy epcoritamab (DuoBody-CD3xCD20) in R/R DLBCL.
- drugepcoritamab (DuoBody-CD3xCD20)
T-cell engaging bispecific antibody administered subcutaneously.
- comparatorinvestigator’s choice chemoimmunotherapy (CIT)
R-GemOx or BR regimens for patients in the control arm.
